PrEP: latest news

PrEP resources

PrEP features

PrEP news from aidsmap

More news

PrEP news selected from other sources

  • Px Wire: Long-Acting Injectables

    In this issue, we review the research on long-acting injectable antiretrovirals for treatment in HIV-positive people and PrEP in HIV-negative people. The pathways for developing these products have key similarities as well as differences—and as the same drugs advance for treatment and PrEP, it will be key to communicate these.

    17 April 2014 | AVAC
  • Petition to Remove AHF's Michael Weinstein for "Party Drug" remark about PrEP

    A former model for one of the AIDS Healthcare Foundation (AHF)'s campaigns has set up an online petition demanding the resignation of Michael Weinstein, Chief Executive of AHF, after he described Truvada pre-exposure prophylaxis as a "party drug".

    16 April 2014 |
  • Op-Ed: The Danger in Calling PrEP a "Party Drug"

    Michael Lucas calls on the president of the AIDS Healthcare Foundation to be removed from his job for remarks about Truvada

    15 April 2014 | Out
  • Why Aren’t Gay Men On The Pill?

    If we can get a critical mass of gay men on either Truvada PrEP or retrovirals, we could soon reach a tipping point in which this virus could be wiped out in a generation.

    10 April 2014 | The Dish
  • Long-acting HIV drugs advanced to overcome adherence challenge

    If it proves effective, long-acting antiretroviral therapy would set up a new paradigm of monthly or quarterly injectable therapy for some patients. Long-acting drug formulations could solve one of the thorniest problems in HIV management - adherence.

    08 April 2014 | Nature Medicine
  • Gay Men Divided Over Use of HIV Prevention Drug

    It's the Truvada conundrum: A drug hailed as a lifesaver for many people infected by HIV is at the heart of a rancorous debate among gay men, AIDS activists and health professionals over its potential for protecting uninfected men who engage in gay sex without using condoms.

    07 April 2014 | ABC News
  • Forgotten Negatives: The Limits of Treatment as Prevention

    The CDC’s High-Impact Prevention strategy takes aim at the stubborn HIV incidence rate in the United States. The only problem: it doesn’t include an ambitious plan for those at risk for the virus.

    02 April 2014 | Treatment Action Group
  • What’s Next for PrEP? A Q&A with Dr. Susan Buchbinder

    San Francisco has been at the forefront of research on PrEP, short for pre-exposure prophylaxis. What PrEP studies are happening in San Francisco right now? And where is PrEP research headed next?

    02 April 2014 | BETA blog
  • HIV Testing Counselor Sells 'Truvada Whore' Shirts For AIDS Charity

    Adam Zebowski, an HIV test counselor at the San Francisco AIDS Foundation, is selling #TruvadaWhore t-shirts at a Kickstarter-style site to help meet his AIDS/Lifecycle fundraising goal of $3000.

    01 April 2014 | Towelroad (blog)
  • 1,000 gay men from Hong Kong and China wanted to trial anti-HIV jab

    A top Aids research team may try to recruit about 1,000 at-risk men from Hong Kong and mainland China for clinical trials of an injection to prevent HIV infection. If it goes ahead it will be the first HIV-prevention clinical trial in China.

    01 April 2014 | South China Morning Post
More news

Our information levels explained

  • Short and simple introductions to key HIV topics, sometimes illustrated with pictures.
  • Expands on the previous level, but also written in easy-to-understand plain language.
  • More detailed information, likely to include medical and scientific language.
  • Detailed, comprehensive information, using medical and specialised language.